EP Patent

EP1621539A1 — Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors

Assigned to Aventis Pharma SA · Expires 2006-02-01 · 20y expired

What this patent protects

The invention relates to the novel products of formula (I): in which V represents a heterocyclic radical.

USPTO Abstract

The invention relates to the novel products of formula (I): in which V represents a heterocyclic radical.

Drugs covered by this patent

Patent Metadata

Patent number
EP1621539A1
Jurisdiction
EP
Classification
—
Expires
2006-02-01
Drug substance claim
No
Drug product claim
No
Assignee
Aventis Pharma SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.